Current status of heart failure: global and Korea

키워드

참고문헌 (59)

1. Coronel R, "Defining heart failure", Cardiovasc Res, 50, pp.419~422 (2001)
2. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
3. Yancy CW, "2013 ACCF", AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation, J Am Coll Cardiol, pp.2013, 62[DOI]
4. Savarese G, "Global public health burden of heart failure", Card Fail Rev, 3, pp.7~11 (2017)
5. Curtis LH, "Incidence and prevalence of heart failure in elderly persons, 1994-2003", Arch Intern Med, 168, pp.418~424 (2008)
6. Virani SS, "Heart disease and stroke statistics-2020 update : a report from the American Heart Association", Circulation, 141, pp.e139~e596 (2020)
7. Dharmarajan K, "Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia", JAMA, 309, pp.355~363 (2013)
8. Mora S, "Evaluation of the pooled cohort risk equations for cardiovascular risk prediction in a multiethnic cohort from the Women’s Health Initiative", JAMA Intern Med, 178, pp.1231~1240 (2018)
9. Jin Joo Park, "Heart Failure Epidemic: an Expected Phenomenon", Korean Circulation Journal, 46(5), pp.610~612 (2016), 대한심장학회
10. Jung Hoon Lee, "Epidemiology of Heart Failure in Korea: Present and Future", Korean Circulation Journal, 46(5), pp.658~664 (2016), 대한심장학회
11. Kim KJ, "Focused update of 2016Korean Society of Heart Failure guidelines for the management of chronic heart failure", Int J Heart Fail, 1, pp.4~24 (2019)
12. 이상언, "Clinical Characteristics and Outcome of Acute Heart Failure in Korea: Results from the Korean Acute Heart Failure Registry (KorAHF)", Korean Circulation Journal, 47(3), pp.341~353 (2017), 대한심장학회
13. 최동주, "Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry", Korean Circulation Journal, 41(7), pp.363~371 (2011), 대한심장학회
14. Park CS, "Characteristics, outcomes, and treatment of heart failure with improved ejection fraction", J Am Heart Assoc, 8, pp.e011077~ (2019)
15. Park JJ, "Characteristics and outcomes of HFpEF with declining ejection fraction", Clin Res Cardiol, 109, pp.225~234 (2020)
16. Owan TE, "Trends in prevalence and outcome of heart failure with preserved ejection fraction", N Engl J Med, 355, pp.251~259 (2006)
17. Lee Y, "Clinical characteristics of Korean patients with congestive heart failure", Korean J Med, 55, pp.446~452 (1998)
18. 한성우, "한국인 심부전 환자의 임상특성 및 예후인자에 관한 다기관 연구.", Korean Circulation Journal, 35(5), pp.357~361 (2005), 대한심장학회
19. 윤종찬, "Temporal Trends of Hospitalized Patients with Heart Failure in Korea", Korean Circulation Journal, 47(1), pp.16~24 (2017), 대한심장학회
20. Sato N, "Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry)", Circ J, 77, pp.944~951 (2013)
21. Fonarow GC, "Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE)", Am Heart J, 153, pp.1021~1028 (2007)
22. Abraham WT, "Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)", J Am Coll Cardiol, 52, pp.347~356 (2008)
23. Nieminen MS, "EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population", Eur Heart J, 27, pp.2725~2736 (2006)
24. Damasceno A, "The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries", Arch Intern Med, 172, pp.1386~1394 (2012)
25. West R, "Characterization of heart failure patients with preserved ejection fraction : a comparison between ADHERE-US registry and ADHERE-International registry", Eur J Heart Fail, 13, pp.945~952 (2011)
26. Okura Y, "Impending epidemic : future projection of heart failure in Japan to the year 2055", Circ J, 72, pp.489~491 (2008)
27. Lee HY, "Paradigm shifts of heart failure therapy:do we need another paradigm?", Int J Heart Fail, 2, pp.e3~ (2020)
28. Packer M, "The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group", N Engl J Med, 334, pp.1349~1355 (1996)
29. CIBIS-II Investigators and Committees, "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial", Lancet, 353, pp.9~13 (1999)
30. SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure", N Engl J Med, 325, pp.293~302 (1991)
31. Pitt B, "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators", N Engl J Med, 341, pp.709~717 (1999)
32. Cohn JN, "A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure", N Engl J Med, 345, pp.1667~1675 (2001)
33. Swedberg K, "Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study", Lancet, 376, pp.875~885 (2010)
34. McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
35. Greenberg B, "Angiotensin receptor-neprilysin inhibition (ARNI) in heart failure", Int J Heart Fail, 2, pp.73~90 (2020)
36. Massie BM, "Irbesartan in patients with heart failure and preserved ejection fraction", N Engl J Med, 359, pp.2456~2467 (2008)
37. Yamamoto K, "Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF)", Eur J Heart Fail, 15, pp.110~118 (2013)
38. Pitt B, "Spironolactone for heart failure with preserved ejection fraction", N Engl J Med, 370, pp.1383~1392 (2014)
39. Solomon SD, "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction", N Engl J Med, 381, pp.1609~1620 (2019)
40. Iribarren C, "Glycemic control and heart failure among adult patients with diabetes", Circulation, 103, pp.2668~2673 (2001)
41. Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study", BMJ, 321, pp.405~412 (2000)
42. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
43. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
44. Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
45. Kato ET, "Sodium-glucose co-transporters-2inhibitors and heart failure : state of the art review and future potentials", Int J Heart Fail, 2, pp.12~22 (2020)
46. Zelniker TA, "SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials", Lancet, 393, pp.31~39 (2019)
47. McMurray JJV, "Dapagliflozin in patients with heart failure and reduced ejection fraction", N Engl J Med, 381, pp.1995~2008 (2019)
48. Halliday BP, "Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial", Lancet, 393, pp.61~73 (2019)
49. Greenspon AJ, "16-Year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008", J Am Coll Cardiol, 58, pp.1001~1006 (2011)
50. Raatikainen MJ, "Current trends in the use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology member countries : 2015 report from the European Heart Rhythm Association", Europace, 17, pp.iv1~iv72 (2015)
51. Ji Hyun Lee, "Temporal Trends of Cardiac Implantable Electronic Device Implantations: a Nationwide Population-based Study", Korean Circulation Journal, 49(9), pp.841~852 (2019), 대한심장학회[DOI]
52. 최홍미, "Update on heart failure management and future directions", The Korean Journal of Internal Medicine, 34(1), pp.11~43 (2019), 대한내과학회[DOI]
53. Holley CT, "Left ventricular assist devices as a bridge to cardiac transplantation", J Thorac Dis, 6, pp.1110~1119 (2014)
54. Banner NR, "UK guidelines for referral and assessment of adults for heart transplantation", Heart, 97, pp.1520~1527 (2011)
55. Mehra MR, "Listing criteria for heart transplantation : International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates : 2006", J Heart Lung Transplant, 25, pp.1024~1042 (2006)
56. Choi DJ, "Artificial intelligence for the diagnosis of heart failure", NPJ Digit Med, 3, pp.54~ (2020)
57. Cleland JGF, "Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction : an individual patient-level analysis of double-blind randomized trials", Eur Heart J, 39, pp.26~35 (2018)
58. Cleland JG, "The perindopril in elderly people with chronic heart failure (PEP-CHF)study", Eur Heart J, 27, pp.2338~2345 (2006)
59. Yusuf S, "Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial", Lancet, 362, pp.777~781 (2003)

관련 논문AI추천